Lupron, Ganirelix, hCG, Omnitrope — the standard IVF protocol is a peptide protocol. The only difference between "fertility medicine" and "research peptides" is who's selling them.
Walk into any fertility clinic in America and you'll get a protocol sheet full of peptides. They just don't call them that. Here's what's actually in the IVF drug cabinet — and what the same molecules are called outside of it.
| Brand Name | Generic / Molecule | Class | IVF Use | Status |
|---|---|---|---|---|
| Lupron | Leuprorelin (leuprolide) | GnRH agonist peptide | Pituitary downregulation | Same molecule |
| Ganirelix | Ganirelix acetate | GnRH antagonist peptide | Premature ovulation prevention | Same molecule |
| Gonal-F | Follitropin alfa | Recombinant glycoprotein hormone | Ovarian stimulation | Same molecule |
| Pregnyl / Ovidrel | hCG (human chorionic gonadotropin) | Peptide hormone | Ovulation trigger | Same molecule |
| Omnitrope | Somatropin (growth hormone) | 191-amino acid peptide | Adjunct for poor responders | Same molecule |
The punchline: Every molecule in the "IVF drugs" column exists as a "research peptide" with identical amino acid sequences. The FDA approves them in one context and treats them as unregulated in another. The molecule doesn't change — only the label does.
Same molecules. Same amino acid sequences. Same mechanism of action. Different rules. The line between "approved fertility drug" and "research chemical" isn't drawn by science — it's drawn by commerce.
GnRH analogues are "FDA-approved medications." Prescribed daily. Covered by some insurance. Administered by nurses. Published in NEJM.
The same GnRH analogues are "research chemicals — not for human consumption." Sold by peptide vendors. Discussed on forums. Viewed with suspicion.
Many fertility peptides are off-patent. Generic competition drives prices down — but also removes the financial incentive for pharma to maintain broad accessibility.
The BPCIA (2020) reclassified hCG as a biologic, eliminating compounding access. Same molecule, new rules, 5-7x price increase overnight.
Kisspeptin is an active IVF trigger in UK clinical trials but has no FDA pathway in the US. Same molecule, same data, different continents, different rules.
FDA-approved fertility drugs generate $7B+ annually. "Research peptides" with identical sequences threaten that revenue model. Regulation follows incentives.
Eleven million Americans are on testosterone replacement therapy. Exogenous testosterone suppresses the HPG axis, shutting down natural sperm production. The result: an ever-growing pipeline of men who need fertility interventions — interventions that are themselves peptide-based.
Testosterone prescribed for low-T symptoms
FSH/LH crash, sperm production stops
Azoospermia, need for IVF/ICSI
hCG, GnRH analogues, enclomiphene
The circular economy of fertility: TRT creates the problem. Peptides solve it. The same patients who might have used peptides (enclomiphene, gonadorelin) to avoid TRT-induced infertility in the first place end up needing different peptides (hCG, GnRH agonists) to reverse it. The molecules could have prevented the problem they're now being used to treat.
Ovarian hyperstimulation syndrome (OHSS) is the most dangerous complication of IVF. It hospitalizes thousands annually and can be fatal. Kisspeptin — a naturally occurring neuropeptide — may eliminate it entirely.
42 healthy babies born. 0% OHSS rate. 62% live birth rate at the optimal 9.6 nmol/kg dose. Standard hCG trigger: ~7% OHSS.
Lancet eBioMedicine (April 2025) published data on intranasal delivery. Non-injectable, patient-friendly, same GnRH-triggering mechanism.
Kisspeptin analogue with longer half-life. Fertility & Sterility (Jan 2024) published Phase 2a results for assisted reproduction applications.
Kisspeptin triggers endogenous GnRH release → natural LH surge → oocyte maturation. Unlike hCG, the signal is self-limiting, preventing the sustained stimulation that causes OHSS.
The most critical safety comparison in modern IVF
Phase 2 data — dose-response relationship
Data from Dhillo et al., Phase 2 (NCT01667406). Dose-response is illustrative based on published optimal dose findings.
Growth hormone (somatropin) is widely used as an IVF adjunct for "poor responders." But the evidence is a battlefield. Depending on which study you read, GH either meaningfully improves outcomes or does absolutely nothing.
2025 umbrella review of meta-analyses found OR 1.80 for live birth with GH co-treatment. Multiple meta-analyses show improved oocyte yield and embryo quality in poor responders.
Mourad 2025 (Human Reproduction): GH in IVF provides no meaningful benefit. The LIGHT study — the largest RCT to date — was stopped for futility. Publication bias suspected.
How the evidence stacks up
The pattern: Meta-analyses of small, heterogeneous studies show benefit. Large, well-designed RCTs show none. This is the classic publication bias signature — small positive studies get published, small negative ones don't. Until another large RCT confirms or denies, GH in IVF remains a $2,000/cycle bet on contested evidence.
Semaglutide (Ozempic/Wegovy) isn't a fertility drug — but its dramatic weight loss effects are reshaping fertility outcomes for women with PCOS. The catch: you have to stop it before getting pregnant.
PCOS is the #1 cause of anovulatory infertility. GLP-1-driven weight loss (15-20% body weight) restores ovulation in many PCOS patients who failed other interventions.
GLP-1 agonists improve insulin resistance — the metabolic driver behind PCOS. Better insulin = lower androgens = restored ovulatory cycles.
Current guidance: discontinue semaglutide at least 2 months before attempting conception. Limited data on fetal exposure. This is non-negotiable.
Anecdotal reports of unexpected pregnancies after starting GLP-1s — weight loss restoring fertility faster than expected. Not evidence, but the pattern is consistent.
⚠️ Critical safety note: GLP-1 receptor agonists are NOT approved for fertility use. The 2-month washout before conception is based on the drug's half-life and limited reproductive toxicity data. Never use during pregnancy or while actively trying to conceive without explicit medical guidance.
In 2020, the FDA reclassified hCG as a biologic under the Biologics Price Competition and Innovation Act (BPCIA). Overnight, compounding pharmacies lost the ability to make affordable hCG. The impact was immediate and devastating.
Price increase for hCG after reclassification. What cost $50-80 now costs $300-500+.
Pharmacies still carrying hCG post-ban. Only 6.7% of surveyed pharmacies maintained stock.
Year of reclassification. BPCIA moved hCG from drug to biologic classification.
Who gets hurt: TRT patients who relied on compounded hCG to maintain fertility. IVF patients facing dramatically higher costs. Male hypogonadism patients who used low-dose hCG for HPG axis preservation. The FDA's stated goal was safety — but the practical result was reduced access and increased cost for the same molecule that had been safely compounded for decades.
⚠️ IMPORTANT DISCLAIMER: The following peptides have NO human fertility trial data. All evidence is from animal models or in-vitro studies. This section exists for scientific completeness, not to suggest clinical use. Do not use these compounds for fertility purposes.
Body Protection Compound-157 has shown tissue-repair properties in animal models across multiple organ systems. Theoretical applications to reproductive tissue repair exist in the literature, but no fertility-specific studies have been conducted. All claims about fertility benefits are speculative extrapolation.
Thymosin β4 expression has been documented in cumulus cells surrounding oocytes and in spermatogonia (sperm precursor cells). This suggests a natural role in reproductive biology — but documenting expression is very different from proving therapeutic benefit. No human fertility data exists.
Expression ≠ therapeutic target. Many proteins are expressed in reproductive tissues without being viable drug targets. These are areas of basic research interest, not actionable clinical data.
Why does the same IVF protocol work brilliantly for one patient and fail completely for another? Increasingly, the answer is pharmacogenomics — genetic variants that affect how your body processes fertility drugs.
| Gene / Variant | What It Affects | Clinical Impact |
|---|---|---|
| FSHR polymorphisms | FSH receptor sensitivity | Ser680Asn variant → 30-50% higher FSH doses needed. Explains "poor responders" who need more gonadotropins for the same ovarian response. |
| GHR variants | Growth hormone receptor | GHR d3 deletion variant → enhanced GH sensitivity. May explain why some patients respond to GH adjunct therapy and others don't. |
| CYP19A1 (aromatase) | Estrogen synthesis from androgens | Polymorphisms affect letrozole/clomiphene response. Variant carriers may need dose adjustments for ovulation induction. |
| LHCGR variants | LH/hCG receptor binding | Affects hCG trigger efficacy and luteal phase support. May partially explain variable OHSS risk between patients. |
| CYP enzymes (2D6, 3A4) | Drug metabolism speed | Ultra-rapid metabolizers clear drugs faster, potentially needing higher doses. Poor metabolizers accumulate drug, increasing side effect risk. |
The future: Pharmacogenomic testing before IVF could personalize protocols — right drug, right dose, first cycle. Some clinics are already testing FSHR variants. Within 5 years, pre-IVF genetic panels may become standard of care.
From the discovery of GnRH to intranasal kisspeptin — 55 years of reproductive peptide science.
Evidence-supported supplements commonly used alongside fertility treatments. These are over-the-counter products — not replacements for medical care.
Looking for research-grade peptides including GnRH analogues, BPC-157, TB-500, and more? Swiss Chems offers third-party tested products for research purposes.
Browse Swiss Chems →Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →Educational content only. Not medical advice. This page is for informational and research purposes only. The peptides and compounds discussed include FDA-approved fertility medications, investigational drugs in clinical trials, and research compounds without human data. Nothing on this page should be interpreted as a recommendation for self-treatment. Fertility treatment requires professional medical supervision. Some compounds mentioned (BPC-157, TB-500) are sold for research purposes only and are not approved for human use. Always consult with a qualified reproductive endocrinologist or fertility specialist before starting any treatment protocol. Clinical trial identifiers (NCT numbers) are provided for verification — look them up at clinicaltrials.gov.